Skip to content

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

Quantitative Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma Undergoing Standard-of-Care FDG-PET/CT for Initial Staging

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04478318
Enrollment
180
Registered
2020-07-20
Start date
2020-06-01
Completion date
2026-12-01
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fluorodeoxyglucose, Lung Neoplasm, Lymphoma, Melanoma, Positron-emission Tomography

Brief summary

To determine the minimum scan duration for fluorine-18 positron-emitting radioactive isotope-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) scans performed on a total-body PET/CT scanner that results in non-inferior image quality to 18F-FDG PET/CT scans performed on a conventional PET/CT scanner. The subject population will be patients being staged for lung cancer, lymphoma, or melanoma.

Interventions

Participants will undergo a total-body PET/CT scan with the uEXPLORER scanner first, followed by a PET/CT scan with the conventional mCT PET/CT scanner.

DEVICEmCT/uEXPLORER

Participants will undergo a PET/CT scan with the conventional mCT PET/CT scanner, followed by a total-body PET/CT scan with the uEXPLORER scanner

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Ability to understand and willingness to sign an informed consent form. 2. Ability to adhere to the study visit schedule and all protocol requirements. 3. Men and women ≥18 years of age. 4. Diagnosis or suspected diagnosis of lung cancer, melanoma or lymphoma. 5. Patients who have been referred for a PET/CT scan.

Exclusion criteria

1. Pregnant women. 2. Claustrophobia. 3. Any significant medical condition that in the opinion of the investigator would prevent the subject from participating and/or adhering to study related procedures or interfere with subject safety.

Design outcomes

Primary

MeasureTime frameDescription
Minimum scan duration on a total-body PET/CT scanner for qualityOne imaging visit up to two hoursTo determine the minimum scan duration for 18F-FDG PET/CT scans performed on a total-body PET/CT scanner that results in non-inferior image quality to 18F-FDG PET/CT scans performed on a conventional PET/CT scanner over 20 minutes.

Secondary

MeasureTime frameDescription
Minimum scan duration on a total-body PET/CT scanner for tumor recognitionOne imaging visit up to two hoursTo determine the minimum scan duration for 18F-FDG PET/CT scans performed on a total-body PET/CT scanner that results in non-inferior tumor conspicuity to 18F-FDG PET/CT scans performed on a conventional PET/CT scanner over 20 minutes (with an additional 2 minutes of data used for optimization purposes).

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLorenzo Nardo, MD

UC Davis Department of Radiology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 7, 2026